Recent research from the City University of Hong Kong (CityUHK) has unveiled critical insights into the “Asian Flush Syndrome,” a condition affecting approximately 40% of the East Asian population. This genetic mutation, known as ALDH2, not only causes alcohol intolerance but also significantly increases the risk of severe heart damage during a heart attack. The findings were published on March 13, 2026, in the prestigious journal Circulation.
Led by Professor Yin Huiyong, the research team has identified the mechanisms by which the ALDH2 mutation triggers a specific type of cell death known as “ferroptosis” during myocardial infarction. This discovery sheds light on why individuals with this genetic mutation experience rapid deterioration of cardiac tissue in the event of a heart attack.
The study involved a clinical analysis of 177 Chinese patients diagnosed with acute heart failure. It revealed that carriers of the ALDH2 mutation showed significantly worse cardiac dysfunction following a heart attack. The team observed clear indicators of ferroptosis, including a marked decrease in Coenzyme Q10, a critical antioxidant for heart health, and an alarming rise in bioactive lipids that contribute to cellular oxidative damage.
Understanding Ferroptosis and Its Impact
Ferroptosis is a unique form of cell death driven by iron ions and lipid peroxidation. In the context of heart health, this process acts like a chain reaction, leading to irreversible damage to myocardial cells and potentially resulting in severe acute heart failure.
The breakthrough of this research lies in the identification of the ALDH2 protein as a “regulator” of cellular functions. Under normal circumstances, ALDH2 interacts with the eIF3E subunit, which is vital for protein synthesis. This interaction helps maintain protein balance within cells. However, the mutation alters this dynamic, causing the eIF3E to switch to a “selective mode” that promotes the production of pathogenic proteins leading to ferroptosis.
The researchers conducted further experiments using animal models to validate these mechanisms. They found that inhibiting ferroptosis through medication or employing genetic technology to control protein translation pathways could enhance cardiac function in mice with the ALDH2 mutation post-heart attack. This suggests potential therapeutic approaches, including existing iron chelators and specific ferroptosis inhibitors, could be developed into targeted treatments for East Asian populations.
Implications for Precision Medicine
This research redefines the role of the ALDH2 protein in cardiac protection and highlights the importance of precision medicine in addressing cardiovascular diseases. In the future, genetic testing could allow clinicians to identify high-risk ALDH2 carriers and implement “anti-ferroptosis” strategies early, improving outcomes for patients experiencing heart attacks.
The collaborative effort included contributions from several prestigious institutions, such as the Shanghai Institute of Nutrition and Health, the Chinese Academy of Sciences, and Tianjin Medical University. This study received support from the National Natural Science Foundation of China, the Shenzhen Medical Research Fund, the Research Grants Council of Hong Kong, and CityUHK.
A dedicated editorial in the same issue of Circulation, authored by renowned cardiovascular scientist Professor Yi Zhu, underscores the transformative nature of this research. Titled “Selective mRNA Translation: A New Player in Ferroptosis After Myocardial Infarction,” the commentary highlights the significant implications of these findings for future medical advancements.
This pioneering study not only deepens the understanding of the ALDH2 mutation’s impact on heart health but also opens new avenues for targeted treatments, potentially benefiting millions of individuals worldwide.
